  See all
 |
Articles: Myeloproliferative Dz |
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma
Blood, 11/06/09
Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma
Leukemia and Lymphoma, 11/06/09 Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma
Leukemia and Lymphoma, 11/06/09
Prior Articles
Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry
Acta Haematologica, 11/04/09
Exclusive Author Commentary Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
Blood, 11/02/09 Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells
Blood, 11/02/09 Mikuliczs disease with severe thrombocytopenia following autologous stem cell transplantation in a multiple myeloma patient
International Journal of Hematology, 10/30/09 Clinical significance of Th1/Th2 ratio in patients with myelodysplastic syndrome
International Journal of Laboratory Hematology, 10/28/09 Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma
Annals of Hematology, 10/27/09 Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09 Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma
Investigational New Drugs, 10/23/09 Iron Chelation Therapy for Patients with Myelodysplastic Syndrome
Hemoglobin, 10/23/09 Prognostic molecular markers in myelodysplastic syndromes
Expert Review of Hematology, 10/22/09
Revew Article
Partial T cell-depleted allogeneic SCT following reduced intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma
Biology of Blood and Marrow Transplantation, 10/22/09 Activation of SHIP via a small molecule agonist kills multiple myeloma cells
Experimental Hematology, 10/22/09 Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma
Cancer Epidemiology, 10/22/09 Thymosin beta4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma
Haematologica, 10/21/09 Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials
Journal of Clinical Oncology, 10/20/09 Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Journal of Clinical Oncology, 10/16/09 Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells
British Journal of Haematology, 10/16/09
|
|
Receive free subspecialty "5-minute updates" via email
|
|
Indexed Journals: Journal of Clinical Oncology, Cancer Research, Annals Oncology
more...
|
187 Available Pages
|
|
